Literature DB >> 29644413

Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension.

Martin Steinmetz1,2, Dominik Nelles3, Jutta Weisser-Thomas3, Christian Schaefer3, Georg Nickenig3, Nikos Werner3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29644413     DOI： 10.1007/s00392-018-1236-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  23 in total

1.  The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension.

Authors:  N Eikelis; D Hering; P Marusic; C Sari; A Walton; S Phillips; E Lambert; J Duval; H Krum; G Lambert; M Esler; M Schlaich
Journal:  Int J Cardiol       Date:  2015-04-07       Impact factor: 4.164

2.  Erratum to: Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry.

Authors:  C Tsioufis; A Ziakas; K Dimitriadis; P Davlouros; M Marketou; A Kasiakogias; C Thomopoulos; D Petroglou; D Tsiachris; M Doumas; E Skalidis; C Karvounis; D Alexopoulos; P Vardas; I Kallikazaros; C Stefanadis; V Papademetriou; D Tousoulis
Journal:  Clin Res Cardiol       Date:  2017-05       Impact factor: 5.460

3.  Eligibility for renal denervation: experience at 11 European expert centers.

Authors:  Alexandre Persu; Yu Jin; Marie Baelen; Eva Vink; Willemien L Verloop; Bernhard Schmidt; Marie K Blicher; Francesca Severino; Grégoire Wuerzner; Alison Taylor; Antoinette Pechère-Bertschi; Fadi Jokhaji; Fadl Elmula M Fadl Elmula; Jan Rosa; Danuta Czarnecka; Georg Ehret; Thomas Kahan; Jean Renkin; Jiři Widimsky; Lotte Jacobs; Wilko Spiering; Michel Burnier; Patrick B Mark; Jan Menne; Michael H Olsen; Peter J Blankestijn; Sverre Kjeldsen; Michiel L Bots; Jan A Staessen
Journal:  Hypertension       Date:  2014-03-24       Impact factor: 10.190

4.  Second denervation in a patient with resistant hypertension.

Authors:  Jose Carlos Prado; Dayan Salado; Luis Miguel Ruilope; Julian Segura
Journal:  Clin Res Cardiol       Date:  2016-06-08       Impact factor: 5.460

5.  Darbepoetin improves endothelial function and increases circulating endothelial progenitor cell number in patients with coronary artery disease.

Authors:  Cornelius Mueller; Karin Wodack; Kaja Twelker; Nikos Werner; Florian Custodis; Georg Nickenig
Journal:  Heart       Date:  2011-06-30       Impact factor: 5.994

Review 6.  Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.

Authors:  Karl Fengler; Karl Philipp Rommel; Thomas Okon; Gerhard Schuler; Philipp Lurz
Journal:  World J Cardiol       Date:  2016-08-26

7.  Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation.

Authors:  Oliver Dörr; Christoph Liebetrau; Helge Möllmann; Luise Gaede; Christian Troidl; Johannes Rixe; Christian Hamm; Holger Nef
Journal:  Hypertension       Date:  2014-01-27       Impact factor: 10.190

8.  Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations.

Authors:  Eline L Vegter; Ekaterina S Ovchinnikova; Dirk J van Veldhuisen; Tiny Jaarsma; Eugene Berezikov; Peter van der Meer; Adriaan A Voors
Journal:  Clin Res Cardiol       Date:  2017-03-14       Impact factor: 5.460

Review 9.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Authors:  Felix Mahfoud; Roland E Schmieder; Michel Azizi; Atul Pathak; Horst Sievert; Costas Tsioufis; Thomas Zeller; Stefan Bertog; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Sebastian Ewen; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Melvin D Lobo; Chaim Lotan; Thomas Felix Lüscher; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Faisal Sharif; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns
Journal:  Eur Heart J       Date:  2017-11-21       Impact factor: 29.983

10.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321
View more
  3 in total

1.  Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension.

Authors:  Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach
Journal:  Clin Res Cardiol       Date:  2019-04-06       Impact factor: 5.460

2.  Patient preference for therapies in hypertension: a cross-sectional survey of German patients.

Authors:  Roland E Schmieder; Karin Högerl; Susanne Jung; Peter Bramlage; Roland Veelken; Christian Ott
Journal:  Clin Res Cardiol       Date:  2019-04-02       Impact factor: 5.460

Review 3.  Patient Selection for Renal Denervation in Hypertensive Patients: What Makes a Good Candidate?

Authors:  Sheran Li; Jacqueline K Phillips
Journal:  Vasc Health Risk Manag       Date:  2022-05-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.